KR102714060B1 - 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 - Google Patents

리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 Download PDF

Info

Publication number
KR102714060B1
KR102714060B1 KR1020187005220A KR20187005220A KR102714060B1 KR 102714060 B1 KR102714060 B1 KR 102714060B1 KR 1020187005220 A KR1020187005220 A KR 1020187005220A KR 20187005220 A KR20187005220 A KR 20187005220A KR 102714060 B1 KR102714060 B1 KR 102714060B1
Authority
KR
South Korea
Prior art keywords
oxaliplatin
irinotecan
leucovorin
liposomal irinotecan
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187005220A
Other languages
English (en)
Korean (ko)
Other versions
KR20180039087A (ko
Inventor
사라 에프 블랑쳇
조나단 바질 피츠제랄드
다니엘 에프 가디
바트 에스 헨드릭스
애쉬쉬 칼라
헬렌 리
앨리엘 베이에버
Original Assignee
입센 바이오팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58100730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102714060(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 입센 바이오팜 리미티드 filed Critical 입센 바이오팜 리미티드
Publication of KR20180039087A publication Critical patent/KR20180039087A/ko
Application granted granted Critical
Publication of KR102714060B1 publication Critical patent/KR102714060B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020187005220A 2015-08-21 2016-08-19 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 Active KR102714060B1 (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562208209P 2015-08-21 2015-08-21
US62/208,209 2015-08-21
US201562216736P 2015-09-10 2015-09-10
US62/216,736 2015-09-10
US201562273244P 2015-12-30 2015-12-30
US62/273,244 2015-12-30
US201662281473P 2016-01-21 2016-01-21
US62/281,473 2016-01-21
US201662302341P 2016-03-02 2016-03-02
US62/302,341 2016-03-02
US201662323245P 2016-04-15 2016-04-15
US62/323,245 2016-04-15
US201662343313P 2016-05-31 2016-05-31
US62/343,313 2016-05-31
PCT/US2016/047727 WO2017034957A1 (en) 2015-08-21 2016-08-19 Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

Publications (2)

Publication Number Publication Date
KR20180039087A KR20180039087A (ko) 2018-04-17
KR102714060B1 true KR102714060B1 (ko) 2024-10-08

Family

ID=58100730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005220A Active KR102714060B1 (ko) 2015-08-21 2016-08-19 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법

Country Status (17)

Country Link
US (5) US20170049775A1 (enExample)
EP (2) EP3337478B1 (enExample)
JP (3) JP2018528185A (enExample)
KR (1) KR102714060B1 (enExample)
CN (1) CN108495629A (enExample)
AU (1) AU2016310476B8 (enExample)
BR (1) BR112018002941B1 (enExample)
ES (1) ES2826826T3 (enExample)
HK (1) HK1257220A1 (enExample)
IL (1) IL257149B2 (enExample)
MX (1) MX385425B (enExample)
PT (1) PT3337478T (enExample)
RU (1) RU2747124C2 (enExample)
SG (1) SG10201913077QA (enExample)
SI (1) SI3337478T1 (enExample)
TW (5) TWI778942B (enExample)
WO (1) WO2017034957A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
JP7113619B2 (ja) * 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
ES2848118T3 (es) 2015-08-20 2021-08-05 Ipsen Biopharm Ltd Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
KR102714060B1 (ko) * 2015-08-21 2024-10-08 입센 바이오팜 리미티드 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions
BR112019007844A2 (pt) * 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
BR112021007318A2 (pt) * 2018-10-17 2021-08-31 Biolinerx Ltd. Tratamento de adenocarcinoma pancreático metastático
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
WO2020170164A1 (en) * 2019-02-22 2020-08-27 Moshe Giladi Treating gastric cancer using ttfields combined with xelox or folfox
JP2022551311A (ja) * 2019-10-10 2022-12-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 活性剤の沈殿物を含む送達系複合体および使用方法
EP4355366A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napoli
EP4355317A4 (en) * 2021-06-16 2025-04-30 Fusion Pharmaceuticals Inc. COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (de) 1996-01-31 1997-08-07 Schering Ag Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6110491A (en) 1996-10-22 2000-08-29 Hermes Biosciences, Inc. Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
BR9914601A (pt) 1998-09-16 2001-10-23 Alza Corp Inibidor de topoisomerase capturado por lipossoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
EP1259225B1 (en) 2000-02-04 2006-10-04 Lipoxen Technologies Limited Process of dehydration/rehydration for making liposomes
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
DE60118547T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
AU2001270385B2 (en) 2000-06-30 2006-05-25 Talon Therapeutics, Inc. Liposomal antineoplastic drugs and uses thereof
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
US7108863B2 (en) 2001-03-26 2006-09-19 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
AU2002328952A1 (en) 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Irinotecan for treatment of cancer
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
MXPA04011871A (es) 2002-05-31 2005-07-26 Transmolecular Inc Quimioterapia en combinacion con clorotoxina.
WO2004035032A2 (en) 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CA2821167C (en) 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
KR100889139B1 (ko) 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2007050784A2 (en) 2005-10-25 2007-05-03 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF
RS53082B (sr) 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. Kombinovana terapija sa parp inhibitorima
CN101442998B (zh) 2006-03-16 2012-03-14 比奥纽默里克药物公司 抗癌活性加强化合物和制剂及其用法
SI2716301T1 (sl) 2007-02-16 2017-07-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in uporaba le-teh
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2187869B1 (en) 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
EP2197917A1 (en) 2007-09-28 2010-06-23 Universitätsspital Basel Immunoliposomes for treatment of cancer
NZ586123A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
RU2010128107A (ru) 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
CA2718918A1 (en) 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US20100022444A1 (en) * 2008-07-24 2010-01-28 Bodybio, Inc. Combination therapy for modulation of activity and development of cells and tissues
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010125462A2 (en) 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
WO2011066684A1 (zh) 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2012012448A1 (en) 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
WO2012012759A2 (en) 2010-07-22 2012-01-26 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
RU2541100C2 (ru) * 2010-09-03 2015-02-10 Боард Оф Регентс Оф Зе Юниверсити Оф Небраска Способ и композиция для лечения рака
EP2648738A2 (en) 2010-12-06 2013-10-16 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
CA2821024A1 (en) 2010-12-14 2012-06-21 Technical University Of Denmark Entrapment of radionuclides in nanoparticle compositions
EP2675918B1 (en) 2011-02-15 2017-11-08 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
AU2012245491C1 (en) 2011-04-19 2017-12-21 Merrimack Pharmaceuticals, Inc. Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
AU2013249307B2 (en) 2012-04-17 2017-11-09 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2013374248A1 (en) 2012-12-14 2015-06-11 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
DK2979700T3 (en) 2013-03-27 2019-01-21 Taiho Pharmaceutical Co Ltd ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE
WO2015031536A1 (en) 2013-08-27 2015-03-05 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
JP7113619B2 (ja) 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
TW201701880A (zh) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法
ES2848118T3 (es) 2015-08-20 2021-08-05 Ipsen Biopharm Ltd Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer
KR102714060B1 (ko) 2015-08-21 2024-10-08 입센 바이오팜 리미티드 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법
WO2017066726A1 (en) 2015-10-16 2017-04-20 Merrimack Pharmaceuticals, Inc. Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
MX394766B (es) 2016-05-18 2025-03-24 Ipsen Biopharm Ltd Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
CN106420789A (zh) * 2016-10-08 2017-02-22 中国人民解放军总医院 复发耐药消化道肿瘤地西他滨综合治疗方案
BR112019007844A2 (pt) 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMC Cancer, 12:199 pp.1-7(2012) 1부.*
The New England Journal of Medicine, 364(19), pp.1817-1825(2011) 1부.*

Also Published As

Publication number Publication date
US11344552B2 (en) 2022-05-31
US20230062425A1 (en) 2023-03-02
HK1257250A1 (en) 2019-10-18
HK1257220A1 (zh) 2019-10-18
TW202243677A (zh) 2022-11-16
IL257149B1 (en) 2024-07-01
RU2018105666A3 (enExample) 2020-02-21
AU2016310476A1 (en) 2018-02-22
WO2017034957A1 (en) 2017-03-02
BR112018002941A2 (pt) 2018-11-27
KR20180039087A (ko) 2018-04-17
JP2022009657A (ja) 2022-01-14
TW201717933A (zh) 2017-06-01
US20240358706A1 (en) 2024-10-31
CN108495629A (zh) 2018-09-04
US20250381191A1 (en) 2025-12-18
EP3337478B1 (en) 2020-08-12
ES2826826T3 (es) 2021-05-19
US20180078556A1 (en) 2018-03-22
JP7463329B2 (ja) 2024-04-08
IL257149A (en) 2018-03-29
EP3337478A1 (en) 2018-06-27
MX385425B (es) 2025-03-18
US20170049775A1 (en) 2017-02-23
RU2018105666A (ru) 2019-09-23
AU2016310476B2 (en) 2021-09-30
JP2024045587A (ja) 2024-04-02
TW202508602A (zh) 2025-03-01
MX2018001802A (es) 2018-05-16
SG10201913077QA (en) 2020-02-27
JP2018528185A (ja) 2018-09-27
BR112018002941B1 (pt) 2023-12-05
PT3337478T (pt) 2020-10-19
CA2993451A1 (en) 2017-03-02
SI3337478T1 (sl) 2020-10-30
AU2016310476B8 (en) 2021-10-07
TWI778942B (zh) 2022-10-01
RU2747124C2 (ru) 2021-04-28
TW202400181A (zh) 2024-01-01
TW202126293A (zh) 2021-07-16
IL257149B2 (en) 2024-11-01
NZ739464A (en) 2024-11-29
EP3791876A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
KR102714060B1 (ko) 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법
RU2761953C2 (ru) Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
CA2993451C (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK40045473A (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK1257250B (en) Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer
HK40009222A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210818

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240112

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240702

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240930

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241002

End annual number: 3

Start annual number: 1

PG1601 Publication of registration